Related Experiment Video

Updated: Jan 23, 2026

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

820

Effectiveness and Safety of Zotarolimus-Eluting Stent (Resolute™ Integrity) in Patients with Diffuse Long Coronary

Keun Ho Park1, Youngkeun Ahn2, Young Youp Koh1

  • 1Division of Cardiology, Department of Internal Medicine, Chosun University Hospital, Gwangju, Korea.

Korean Circulation Journal
|June 6, 2019
PubMed

Insights

Resolute™ zotarolimus-eluting stents (R-ZES) show excellent 1-year outcomes for diffuse long coronary artery disease (DLCAD) patients in Korea. The study found low rates of major adverse cardiac events (MACE) and stent thrombosis.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Biomedical Engineering

Background:

  • Diffuse long coronary artery disease (DLCAD) presents challenges with unfavorable outcomes post-percutaneous coronary intervention (PCI).
  • Evaluating novel stent technologies is crucial for improving DLCAD management.
  • The Resolute™ zotarolimus-eluting stent (R-ZES) offers a potential solution for complex coronary lesions.

Purpose of the Study:

  • To assess the effectiveness and safety of the Resolute™ zotarolimus-eluting stent (R-ZES) in patients with DLCAD.
  • To determine the 12-month incidence of major adverse cardiac events (MACE) following R-ZES implantation for DLCAD.
  • To identify predictors of MACE in this patient cohort.

Main Methods:

  • A prospective study involving 1,011 patients undergoing PCI with R-ZES for lesions >25 mm in Korea (December 2011-December 2014).
  • Major adverse cardiac events (MACE) were defined as cardiac death, non-fatal myocardial infarction, or target vessel revascularization.
  • Clinical outcomes were analyzed at 12 months post-procedure.

Main Results:

  • The study included a significant cohort with a mean age of 63.8 years, predominantly male (69.3%), with high rates of hypertension (87.0%) and multi-vessel disease (53.9%).
  • A total of 1,697 R-ZES were implanted in 1,472 lesions, with overlapping stents used in 13.8% of cases.
  • The 12-month incidence of MACE was 3.0%, and definite stent thrombosis was 0.3%. Independent predictors of MACE included multiple overlapping stents, prior heart failure, multi-vessel disease, and age ≥75 years.

Conclusions:

  • The Resolute™ zotarolimus-eluting stent (R-ZES) demonstrates excellent 1-year clinical outcomes in Korean patients with diffuse long coronary artery disease (DLCAD).
  • The safety and efficacy profile of R-ZES supports its use in managing complex coronary artery lesions.
  • Identifying predictors of MACE can aid in risk stratification and personalized treatment strategies for DLCAD patients.
Abstract

Keywords:
Coronary artery diseaseDrug-eluting stentsTreatment outcome

More Related Videos

Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis08:26

Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis

Published on: January 21, 2020

7.2K
Implantation of Human-Sized Coronary Stents into Rat Abdominal Aorta Using a Trans-Femoral Access05:04

Implantation of Human-Sized Coronary Stents into Rat Abdominal Aorta Using a Trans-Femoral Access

Published on: November 19, 2020

4.8K

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
922
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
391
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
223
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
345
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
609
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
335